|Last Price$160.60||Day Change (%)-0.58%|
|Open Price$161.77||Day Change ($)-0.93|
|Day Range160.45–162.28||52-Week Range100.89–185.43|
As of Thu 09/18/2014 01:51 PM EST | USD
Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years
NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England
Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation
We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.
Ownership data provide a look at who else owns the company.
Standing out in a good year for stocks.
Week ending Nov. 10: Investors remain optimistic about direction of economy.
Buying a country or sector fund isn't as easy as it seems.